作者
Alberto J Espay, Francesca Morgante, Aristide Merola, Alfonso Fasano, Luca Marsili, Susan H Fox, Erwan Bezard, Barbara Picconi, Paolo Calabresi, Anthony E Lang
发表日期
2018/12
来源
Annals of Neurology
卷号
84
期号
6
页码范围
797-811
简介
Levodopa‐induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa‐to‐dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine‐releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in‐development treatments for peak‐dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811
学术搜索中的文章
AJ Espay, F Morgante, A Merola, A Fasano, L Marsili… - Annals of Neurology, 2018